Jefferies Financial Group Inc. purchased a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 600,000 shares of the company's stock, valued at approximately $1,590,000. Jefferies Financial Group Inc. owned about 2.08% of Aerovate Therapeutics at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. GTS Securities LLC purchased a new position in shares of Aerovate Therapeutics in the fourth quarter worth $27,000. Ieq Capital LLC acquired a new stake in shares of Aerovate Therapeutics in the fourth quarter valued at about $38,000. Russell Investments Group Ltd. boosted its position in Aerovate Therapeutics by 110.7% during the fourth quarter. Russell Investments Group Ltd. now owns 15,184 shares of the company's stock worth $40,000 after acquiring an additional 7,977 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Aerovate Therapeutics during the fourth quarter worth about $52,000. Finally, Harvest Investment Services LLC acquired a new position in Aerovate Therapeutics during the fourth quarter worth about $63,000.
Aerovate Therapeutics Stock Performance
Shares of Aerovate Therapeutics stock traded down $0.16 on Friday, reaching $7.09. The company had a trading volume of 372,015 shares, compared to its average volume of 18,821. The firm's 50 day moving average price is $51.43 and its two-hundred day moving average price is $76.16. The firm has a market cap of $205.50 million, a PE ratio of -2.37 and a beta of 0.95. Aerovate Therapeutics, Inc. has a 52-week low of $43.75 and a 52-week high of $884.98.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last issued its earnings results on Friday, April 25th. The company reported ($3.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($10.50) by $7.35. As a group, sell-side analysts predict that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current year.
Aerovate Therapeutics Announces Dividend
The firm also recently disclosed a dividend, which was paid on Monday, April 28th. Investors of record on Friday, April 25th were paid a $84.00 dividend. The ex-dividend date of this dividend was Tuesday, April 29th.
Aerovate Therapeutics Company Profile
(
Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
